<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83913">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01826149</url>
  </required_header>
  <id_info>
    <org_study_id>20120925</org_study_id>
    <nct_id>NCT01826149</nct_id>
  </id_info>
  <brief_title>Propofol Effects on Mitral Valve Annular Velocity</brief_title>
  <official_title>The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is primarily to determine the effects of propofol at different
      concentration on the mitral valve annulus by using  Tissue Doppler Imaging
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effects of different concentration of propofol
      on patients who are undergoing cardiac surgery. The patients will receive infusion
      remifentanil 0.5mcg/kg/min with different target-site propofol concentration namely
      1.0ng/ml, 2.0ng/ml and 3.0ng/ml. Tissue Doppler Imaging by transesophageal echocardiography
      will be done to assess the changes in cardiac function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of systolic mitral valve annular velocity (S')</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
    <safety_issue>No</safety_issue>
    <description>To examine the effect of Propofol at different effect-site concentration ( 1.0 ng/ml, 2.0 ng/ml and 3.0 ng/ml) on S'  (systolic mitral valve annular velocity) during remifentanil-based anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early diastolic mitral valve annular velocity (e')</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late diastolic (atrial contractile) mitral valve annular velocity (a')</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ejection fraction</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phenylephrine infusion rate</measure>
    <time_frame>10 min after achieving 3 different propofol concentrations</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Valvular Heart Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0ng/ml, 2.0ng/ml and 3.0ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>Propofol dosage titration to achieve effect site concnetration 1.0 ng/ml, 2.0 ng/ml and 3.0 ng/ml using target controlled infusion</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Fresofol (2% propofol, Fresinius Kabi)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients undergoing cardiac surgery

        Exclusion Criteria:

        low ejection fraction &lt; 50% on transthoracic echocardiography atrial fibrillation
        pacemaker pericardial and infiltrative myocardial disease mitral annular calcification,
        surgical rings, prosthetic mitral valve lateral left ventricular wall motion abnormality
        oesophageal abnormality history of extensive radiation to the mediastinum upper
        gastrointestinal bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-yop Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center, Seoul, Korea, Republic of</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae-Yop Kim, M.D, PhD</last_name>
    <email>pondkim@unitel.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-yop Kim, M.D, PhD</last_name>
      <email>pondkim@unitel.co.kr</email>
    </contact>
    <investigator>
      <last_name>Tae-Yop Kim, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeongho Seok, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 28, 2013</lastchanged_date>
  <firstreceived_date>March 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
